Viatris Earnings Reports

Viatris delivered total revenues in line with expectations, demonstrating strength in its base business. The company made significant pipeline progress with three positive Phase 3 data readouts and returned more than $450 million in capital to shareholders year-to-date, reaffirming its 2025 capital allocation priorities. Despite a U.S. GAAP net loss driven by a goodwill impairment charge, adjusted net earnings and adjusted EBITDA were positive.

Viatris posted Q4 2024 revenue of $3.52 billion, reflecting an 8% decline year-over-year. The company reported a GAAP net loss of $516.5 million and adjusted EPS of $0.54. While the Greater China segment showed positive growth, other geographic regions and product categories experienced declines.

Viatris reported strong Q3 2024 results with total revenues of $3.8 billion, including $133 million from new products. The company repaid approximately $1.9 billion in debt and expanded its innovative portfolio through an exclusive licensing agreement for sotagliflozin. Adjusted EBITDA grew by ~4% to $1.3 billion on a divestiture-adjusted basis, and adjusted EPS grew by ~6% to $0.75 per share on a divestiture-adjusted basis. The company reaffirms its 2024 full-year outlook, expecting revenue growth of ~2% on a divestiture-adjusted operational basis.